Recently, studies have reported that aspirin has chemopreventive properties. In this study, we used the Taiwan NHI database, which covers a population of 23 million (99.99%) Taiwanese from 2001 to 2011. This was a case–control study which identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. Each case with 4 eligible controls was matched for age, sex, and index date and adjusted for confounding factors. The observed overall cancer risk (adjusted OR (AOR), 0.95; 95% CI 0.94 to 0.96) reduced with aspirin use, specifically, colorectal (AOR, 0.97; 95% CI 0.94 to 0.99) and digestive system (AOR, 0.96; 95% CI 0.94 to 0.98) cancers. Findings from the Asian population would contribute to the discussion on aspirin's safety profile.
- Drugs, Investigational
- Drug-Related Side Effects and Adverse Reactions
Statistics from Altmetric.com
Contributors Y-CL, UI, and H-CY designed the study, enrolled patients, interpreted data, wrote the report, and approved the final draft. UI, H-CY, and W-SJ designed the study, searched the published work, analyzed and interpreted data, reviewed the manuscript, and approved the final draft. Y-CL, W-SJ, and YY interpreted data, reviewed the report, and approved the final draft.
Funding This research is sponsored in part by Ministry of Science and Technology (MOST) under grant MOST 104-2221-E-038–013, MOST 104–3011-E-038-001, Health and welfare surcharge of tobacco products grant MOHW105-TDU-B-212-134001, and Ministry of Education, Taiwan, under grant TMUTOP103006-6.
Competing interests None declared.
Ethics approval Ethical approval was not required as we used anonymous data.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.